Get the Stockscreener App
1.455
3.55%
0.045
Ocugen Inc stock is traded at $1.455, with a volume of 4.07M.
It is up +3.55% in the last 24 hours and up +26.96% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.41
Open:
$1.46
24h Volume:
4.07M
Relative Volume:
0.82
Market Cap:
$454.43M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-5.3889
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+12.31%
1M Performance:
+26.96%
6M Performance:
+33.94%
1Y Performance:
+93.51%
1-Day Range:
$1.44
$1.58
1-Week Range:
$1.30
$1.58
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.455 | 440.37M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.23 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.97 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.42 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.61 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.24 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Why Ocugen Inc. stock is a must watch in 2025July 2025 Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Why pension funds invest in Ocugen Inc. (2H51) stockAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Ocugen Shares Face Mounting Pressure Amid Financial Concerns - AD HOC NEWS
Ocugen Inc. Stock Rises Tuesday, Outperforms Market - 富途牛牛
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - Zacks Investment Research
Ocugen (NASDAQ:OCGN) Shares Up 1.5%What's Next? - MarketBeat
Ocugen Inc. Stock Rises Monday, Outperforms Market - 富途牛牛
How The Latest Analyst Shifts Are Reshaping Ocugen’s Story and Valuation - Yahoo Finance
Ocugen Inc Stock Analysis and ForecastSector Rotation Strategies & Free Rapid Growing Investment Returns - earlytimes.in
Growth Recap: Is Ocugen Inc stock supported by strong cash flowsJuly 2025 Review & Stepwise Trade Execution Plans - moha.gov.vn
Institutional Giant Janus Henderson Makes Major Bet on Ocugen - AD HOC NEWS
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Ocugen I - GuruFocus
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen CEO’s Keynote Address Meets Heightened Market Skepticism - Ad-hoc-news.de
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen, Inc. Chairman and CEO Dr. Shankar Musunuri to Present at Oppenheimer Movers in Rare Disease Summit - Quiver Quantitative
Major Fund Manager Acquires Significant Stake in Ocugen Amid Share Price Weakness - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. Stock Falls Friday, Underperforms Market - 富途牛牛
Institutional Backing and Geopolitical Tailwinds for Ocugen - AD HOC NEWS
Ocugen Secures Validating Partnership for Gene Therapy Platform - AD HOC NEWS
How robust is Ocugen Inc. (2H51) stock financial positionMarket Volume Summary & Long Hold Capital Preservation Tips - Newser
Why institutional investors increase stakes in Ocugen Inc. (2H51) stockJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
How Ocugen Inc. (2H51) stock compares with tech leadersEarnings Growth Summary & Weekly Hot Stock Watchlists - Newser
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Is Ocugen Inc. (2H51) stock resilient in recession scenarios2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
Why Ocugen Inc. stock appeals to analystsWeekly Trade Analysis & Risk Controlled Swing Alerts - Newser
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference - MSN
Can Ocugen Inc. (2H51) stock deliver consistent EPS growth2025 Volatility Report & Safe Capital Growth Stock Tips - Newser
Is Ocugen Inc. (2H51) stock good for long term investingRisk Management & Free Community Consensus Stock Picks - Newser
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments - Yahoo Finance
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MSN
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen Inc 2H51 Stock Analysis and ForecastEarnings Surprise Analysis & Low Cost Capital Trading - earlytimes.in
Ocugen, Inc.Common Stock (NQ: OCGN - Markets Financial Content
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Stock Price and Chart — NASDAQ:OCGN - TradingView
Ocugen, Inc. (OCGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Ocugen Inc. (2H51) stock outperform energy sector in 20252025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Is Ocugen Inc. stock a defensive play in 20252025 Dividend Review & Real-Time Market Trend Scan - newser.com
Why retail investors favor Ocugen Inc. stockWeekly Trend Summary & AI Forecasted Stock Moves - newser.com
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - Ocugen
How Ocugen Inc. (2H51) stock trades after rate cuts2025 Price Action Summary & Verified Technical Signals - newser.com
Ocugen CEO to Present at NobleCon21-Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - The Manila Times
Ocugen CEO Dr. Shankar Musunuri to Present at NobleCon21 Conference on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth ... - Herald and News
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ - GlobeNewswire
Why Ocugen Inc. (2H51) stock could outperform next yearPortfolio Value Summary & AI Optimized Trading Strategy Guides - newser.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):